VTRS Viatris

Q1 2025 10-Q

Filed: May 8, 2025Period ending Mar 31, 2025

Health Care

Pharmaceutical PreparationsSEC EDGAR

Viatris (VTRS) 10-Q quarterly report for Q1 2025, filed with SEC EDGAR on May 8, 2025 for the fiscal period ending Mar 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q1 2025 10-Q

Risk Factors

• New risk: Potential U.S. tariffs on pharmaceutical imports triggered by recent tariff escalations and retaliations from other countries
• Most material update: Increased cost and supply chain disruption risk from proposed tariffs affecting generics, possibly reducing net sales and profit margins

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$3.2B

Net Income

-$3.0B

Net Margin

-93.8%

Source: XBRL data from Viatris Q1 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Viatris Quarterly Reports

Q3 2025 10-Q

Get deeper insights on Viatris

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.